Peptomyc SL
- Biotech or pharma, therapeutic R&D
Peptomyc is a clinical stage company focused on the development of a new generation of cell penetrating proteins (CPPs) targeting MYC, the most dysregulated oncogene in human cancer. MYC holds a non-redundant function in cancer around which tumours cannot evolve, hence targeting MYC is the most promising therapeutic opportunity to date. Despite that, there is currently no MYC inhibitor in the market.
Our lead compound, OMO-103, is the first MYC inhibitor to have successfully completed a Phase I clinical trial in all-comers solid tumours and is now being tested in a Phase Ib combination study with SOC chemotherapy in mPDAC, and in a Phase 2 study in monotherapy in advanced osteosarcoma,
Combinations with KRASi and PARPi are being explored as well.
Peptomyc is now expanding its pipeline to include radioligands and miniprotein therapeutics for brain tumors and brain metastases, among others.
Our series C round of investment is currently open.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}